A multitude of physiological effects and putative pathophysiological roles have been proposed for the endogenous cannabinoid system in the gastrointestinal tract, liver and pancreas. These range from effects on epithelial growth and regeneration, immune function, motor function, appetite control, fibrogenesis and secretion. Cannabinoids have the potential for therapeutic application in gut and liver diseases. Two exciting therapeutic applications in the area of reversing hepatic fibrosis as well as antineoplastic effects may have a significant impact in these diseases. This review critically appraises the experimental and clinical evidence supporting the clinical application of cannabinoid receptor-based drugs in gastrointestinal, liver and pancreatic diseases. Application of modern pharmacological principles will most probably expand the selective modulation of the cannabinoid system peripherally in humans. We anticipate that, in addition to the approval in several countries of the CB(1) antagonist, rimonabant, for the treatment of obesity and associated metabolic dysfunctions, other cannabinoid modulators are likely to have an impact on human disease in the future, including hepatic fibrosis and neoplasia.

Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects / Izzo, ANGELO ANTONIO; M., Camilleri. - In: GUT. - ISSN 0017-5749. - STAMPA. - 57:(2008), pp. 1140-1155.

Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects

IZZO, ANGELO ANTONIO;
2008

Abstract

A multitude of physiological effects and putative pathophysiological roles have been proposed for the endogenous cannabinoid system in the gastrointestinal tract, liver and pancreas. These range from effects on epithelial growth and regeneration, immune function, motor function, appetite control, fibrogenesis and secretion. Cannabinoids have the potential for therapeutic application in gut and liver diseases. Two exciting therapeutic applications in the area of reversing hepatic fibrosis as well as antineoplastic effects may have a significant impact in these diseases. This review critically appraises the experimental and clinical evidence supporting the clinical application of cannabinoid receptor-based drugs in gastrointestinal, liver and pancreatic diseases. Application of modern pharmacological principles will most probably expand the selective modulation of the cannabinoid system peripherally in humans. We anticipate that, in addition to the approval in several countries of the CB(1) antagonist, rimonabant, for the treatment of obesity and associated metabolic dysfunctions, other cannabinoid modulators are likely to have an impact on human disease in the future, including hepatic fibrosis and neoplasia.
2008
GUT
Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects / Izzo, ANGELO ANTONIO; M., Camilleri. - In: GUT. - ISSN 0017-5749. - STAMPA. - 57:(2008), pp. 1140-1155.
File in questo prodotto:
File Dimensione Formato  
izzo and camilleri 2008 GUT.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: Accesso privato/ristretto
Dimensione 996.3 kB
Formato Adobe PDF
996.3 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/333362
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 195
  • ???jsp.display-item.citation.isi??? 166
social impact